Journal of Gastroenterology

, Volume 49, Issue 11, pp 1485–1494

Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study

  • Noritomo Shimada
  • Hidenori Toyoda
  • Akihito Tsubota
  • Tatsuya Ide
  • Koichi Takaguchi
  • Keizo Kato
  • Masaki Kondoh
  • Kazuhiro Matsuyama
  • Takashi Kumada
  • Michio Sata
Original Article—Liver, Pancreas, and Biliary Tract

DOI: 10.1007/s00535-013-0918-7

Cite this article as:
Shimada, N., Toyoda, H., Tsubota, A. et al. J Gastroenterol (2014) 49: 1485. doi:10.1007/s00535-013-0918-7
  • 272 Views

Abstract

Background

Genetic polymorphisms near Interleukin 28B (IL28B) (rs8099917) and a rapid virological response (RVR) have been reported as predictors for a sustained virological response (SVR) to telaprevir (TVR)-based triple combination therapy. However, the association between SVR and viral kinetics earlier than week 4 after initiation of therapy remains unclear. Thus, we evaluated the SVR prediction ability of baseline factors and reduced hepatitis C virus (HCV) RNA levels at week 1 after the initiation of TVR-based therapy in Japanese genotype-1b chronic hepatitis C (CHC) patients.

Methods

A total of 156 Japanese CHC patients received a 24-week regimen of TVR-based therapy. Baseline factors and reduction in HCV RNA levels at weeks 1 and 4 after the initiation of therapy were analyzed for SVR prediction.

Results

Multiple logistic regression analysis for SVR in TVR-based therapy identified the IL28B TT genotype, a reduction of ≥4.7 log10IU/mL in HCV RNA levels at week 1, RVR, and treatment-naïve/relapse. Whereas the SVR rate was higher than 90 % regardless of the reduction in HCV RNA levels at week 1 in patients with the TT genotype, a reduction of ≥4.7 log10IU/mL in HCV RNA levels at week 1 was the strongest predictor of SVR in patients with the non-TT genotype, as determined by multiple logistic regression analysis (P = 0.0043).

Conclusions

The IL28B TT genotype is the most important baseline factor for predicting SVR, and a ≥4.7 log10IU/mL reduction in HCV RNA at week 1 is a useful very early on-treatment predictor of SVR, especially in the non-TT genotype.

Keywords

Chronic hepatitis CReduction in HCV RNA at week 1TelaprevirIL28B

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Noritomo Shimada
    • 1
  • Hidenori Toyoda
    • 2
  • Akihito Tsubota
    • 3
  • Tatsuya Ide
    • 4
  • Koichi Takaguchi
    • 5
  • Keizo Kato
    • 1
  • Masaki Kondoh
    • 6
  • Kazuhiro Matsuyama
    • 6
  • Takashi Kumada
    • 2
  • Michio Sata
    • 4
  1. 1.Division of Gastroenterology and HepatologyShinmatsudo Central General HospitalMatsudoJapan
  2. 2.Department of GastroenterologyOgaki Municipal HospitalOgakiJapan
  3. 3.Institute of Clinical Medicine and ResearchJikei University School of MedicineKashiwaJapan
  4. 4.Division of Gastroenterology, Department of MedicineKurume University School of MedicineKurumeJapan
  5. 5.Department of HepatologyKagawa Prefectural Central HospitalTakamatsuJapan
  6. 6.Department of Life Cycle ManagementRoche Diagnostics K.KTokyoJapan